Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT02885597 Recruiting - Clinical trials for Rheumatoid Arthritis

Juanbi Pill for Rheumatoid Arthritis

Start date: July 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether Juanbi Pill combined with methotrexate are effective in the treatment of active Rheumatoid Arthritis (RA).

NCT ID: NCT02876874 Recruiting - Clinical trials for Rheumatoid Arthritis

Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage

Start date: December 2014
Phase: N/A
Study type: Observational [Patient Registry]

To observe the relationship between the activity of rheumatoid arthritis and popliteal/epitrochlear lymph node morphology and the drainage of hand/foot superficial lymphatic vessels

NCT ID: NCT02837146 Recruiting - Clinical trials for Rheumatoid Arthritis

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

TOVERA
Start date: December 2015
Phase: Phase 3
Study type: Interventional

This study is aimed at assessing the kinetics of the ultrasound (US) response in DMARD-naive very early rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and methotrexate (MTX).

NCT ID: NCT02804581 Recruiting - Clinical trials for Rheumatoid Arthritis

Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients

Start date: June 2016
Phase: Phase 2
Study type: Interventional

Gum Arabic (GA) rich dietary fiber it is a water-soluble dietary fiber derived from the dried gummy exudates of the stems and branches of Acacia senegal, GA found to have strong immuno modulator in vitro where it increased IL10 production showing strong anti-inflammatory effects (19). The aim of this study is to determine the role of gum Arabic in immunomodulation among patients with rheumatoid arthritis.

NCT ID: NCT02804204 Recruiting - Clinical trials for Rheumatoid Arthritis

Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

AROMA
Start date: June 2016
Phase:
Study type: Observational

Multicenter, prospective, observational study for evaluating if circulant rheumatoid factor, cyclic citrullinated anti-peptide anti-bodies and albumin can be used as potential predictors in the response to the treatment with anti-TNF in patients with rheumatoid arthritis after 24 weeks of treatment.

NCT ID: NCT02787538 Recruiting - Clinical trials for Rheumatoid Arthritis

Supporting Patient Care With Electronic Resources in the United States

SuPER-US
Start date: January 2016
Phase: N/A
Study type: Interventional

This proof-of-concept randomized trial evaluates the effectiveness of using an online decision aid (US-ANSWER-2) in the decision-making to start or switch biologic therapy in US patients with rheumatoid arthritis.

NCT ID: NCT02783274 Recruiting - Clinical trials for Rheumatoid Arthritis

Actis Total Hip System 2 Year Follow-up

Actis14014
Start date: July 1, 2016
Phase: N/A
Study type: Interventional

Two-year (2 year) information regarding the performance of the commercially available Actis™ Total Hip System in order to obtain and evaluate the clinical outcomes on a series of cementless primary total hip arthroplasty (THA) and hemi-hip arthroplasty procedures using clinical, radiographic and device and procedure related adverse event assessments.

NCT ID: NCT02779114 Recruiting - Clinical trials for Rheumatoid Arthritis

RETRO (REduction of Therapy in RA Patients in Ongoing Remission)

RETRO
Start date: January 2009
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, open, prospective, controlled, parallel-group intervention study in 318 patients with Rheumatoid Arthritis. The study is composed of 3 phases: a pre-randomization phase for up to 10 days followed by a 1-year randomized, open three arm treatment phase for each patient, followed by a 5-year observational phase for all patients still in remission.

NCT ID: NCT02765074 Recruiting - Clinical trials for Rheumatoid Arthritis

Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis

REPAIR
Start date: June 30, 2016
Phase: Phase 4
Study type: Interventional

Rheumatoid arthritis (RA) is a chronic inflammatory disease mediated by the production of several cytokines, which leads to the destruction of bone and cartilage tissue in multiple joints and to bone loss. Conventional radiographs (CR) are considered as the gold standard for diagnosis and follow up of joint changes in RA. But this method has low sensitivity to detect early erosive changes and is unable to evaluate periarticular bone loss. High Resolution peripheral QCT (HRpQCT) enables the detection of erosions less than 0.5 mm in width or depth at metacarpo-phalangeal (MCP) joints. Using 3-D high resolution analysis of cortical bone erosions, this one is also able to evaluate the volumes of erosion and the evolution under treatments IL6 (6- interleukin) plays a major role in inflammatory process and bone damages related to RA. Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody, developed and investigated in several clinical trials in RA. This biotherapy, in association with methotrexate (MTX) or given in monotherapy, is efficient in RA with inadequate response to MTX or anti-TNF b (tumor necrosis factor). TCZ reduces dramatically systemic inflammation, structural progression and improves clinical symptoms and quality of life. Tocilizumab may help reducing bone erosions, periarticular osteopenia and systemic bone loss.

NCT ID: NCT02764515 Recruiting - Clinical trials for Rheumatoid Arthritis

Kunxian for the Treatment of Rheumatoid Arthritis

Start date: September 2015
Phase: Phase 4
Study type: Interventional

This is a multicenter, randomized, double blind, double-dummy and controlled clinical trial aimed to compare the clinical efficacy and safety of Kunxian Capsule, a compound of Chinese traditional medicine, and the active comparator,Methotrexate for the treatment of rheumatoid arthritis. The primary end-point is that Kunxian Capsule is not inferior to Methotrexate both in efficacy and safety.